Laboratory Corporation of America has signed an agreement with Maryland-based Celera to license two genomics-based tests for use in oncology.
The tests are for prediction of metastasis risk in early-stage breast cancer patients and in the selection of women for endocrine therapy. Celera announced discoveries related to the testing technology in June of last year.
Financial terms were not disclosed.
“This license agreement with Celera strategically complements our innovative and extensive pipeline of diagnostic services and reinforces our strong commitment to genetic and molecular oncology testing,” said Myla Lai-Goldman, LabCorp’s chief scientific officer and medical director. “Applying Celera’s findings in breast cancer to the development of new tests supports our ever-growing menu of esoteric and genomic tests, and underscores our commitment to bring relevant clinical tests to market.”
